Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
107 results about "Immune inflammation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Inflammation is a vital part of the immune system's response to injury and infection. It is the body's way of signaling the immune system to heal and repair damaged tissue, as well as defend itself against foreign invaders, such as viruses and bacteria.
8-Substituted Benzoazepines as Toll-Like Receptor Modulators
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and / or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
Owner:ARRAY BIOPHARMA
Compositions and methods relating to novel compounds and targets thereof
InactiveUS20060025388A1Raise active oxygen levelsReduce activationBiocideHydroxy compound active ingredientsBenzodiazepineAutoimmune responses
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
Owner:RGT UNIV OF MICHIGAN
Methods and compositions for treating diseases and conditions associated with mitochondrial function
InactiveUS20090275099A1Reduce activationInhibits keratinocyte proliferationOrganic active ingredientsOrganic chemistryATP HydrolaseDisease
The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase associated disorders, and the like.
Owner:RGT UNIV OF MICHIGAN
Toll like receptor modulators
ActiveUS20090053148A1Prevent diseaseLower immune responseSenses disorderNervous disorderInflammatory Bowel DiseasesAutoimmune responses
The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
Owner:IDERA PHARMA INC
Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
ActiveUS20070111994A1Rapid and easy identificationReduce the amount requiredBiocideAntipyreticDiketoneBenzene
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.
Owner:RGT UNIV OF MICHIGAN
Toxic aldehyde related diseases and treatment
ActiveUS20150335632A1Reduce the risk of diseasePrevention reductionBiocideCosmetic preparationsCvd riskBlisters
The present invention provides for the treatment, prevention, and / or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Owner:ALDEYRA THERAPEUTICS
Applications of andrographolide derivatives and 3,19 esterified compounds thereof in preparation of anti-hepatic fibrosis medicines
ActiveCN106946821ADefinitive anti-hepatic fibrosis activityInhibit migrationOrganic active ingredientsOrganic chemistryCell-Extracellular MatrixHepatic stellate cell activation
The invention belongs to the technical field of medicines, discloses applications of andrographolide derivatives in preparation of medicines preventing and treating hepatic fibrosis, and relates to 15-benzylidene-14-deoxy-11,12-dehydroandrographolide derivatives and 3,19 esterified compounds thereof. Experiments prove that the compounds significantly inhibit human hepatic stellate cell LX-2 metastasis and activation, significantly reduce the fibrosis level of hepatic tissues of rats affected with hepatic fibrosis, reduce contents of extracellular matrix protein (ECM) related components, significantly reduce the level of immune inflammation correlation factors of rats affected with hepatic fibrosis, effectively inhibit immuno-inflammatory responses, inhibit hepatic stellate cell activation in hepatic tissues, and promote collagen degradation. The compounds are used as active components for preparing the anti-hepatic fibrosis medicines, and are efficient and low in toxicity, thus providing a novel medicine route for hepatic fibrosis treatment and prevention, and expanding the optional range of clinical medicine application. The compounds and the applications have good development prospects.
Owner:ZHENGZHOU UNIV
T cell regulatory genes associated with immune disease
InactiveUS20050095593A1Diminish and terminate immunological disorderAvoid developmentImmunoglobulin superfamilySugar derivativesInflammatory Bowel DiseasesAutoimmune responses
A genetic locus and corresponding family of proteins associated with regulation of immune development, function, and cell survival are provided. The locus comprising the TIM family is genetically associated with immune dysfunction, including atopy, autoimmunity, inflammatory bowel disease, dysplasia, and susceptibility to blood-bourne infectious diseases. Polymorphisms in the human TIM-1 gene and exposure to Hepatitis A Virus (HAV) are shown to be associated with protection from the development of atopy.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Deuterated compounds and uses thereof
Owner:ALDEYRA THERAPEUTICS
Antimicrobial antiphlogistic antagonism polypeptide simulating MD2
InactiveCN101245098AAntibacterial agentsPeptide/protein ingredientsBiological activationInflammatory cell
The invention provides an antagonistic peptide which can simulate the key sequence for bonding MD2 and LPS and competitively antagonize the specific bonding which is generated by LPS and MD2, thus achieving the mitigation of the excessive activation of the immune inflammatory cells of LPS and further easing the caused excessive septic damages to the body. The amino acid sequence of the antagonist peptide includes: a sequence 1 of Lys Thr Val Pro Asp Asn His; and the sequence 2 of Ile Gly Lys Phe Leu Tyr Arg. The peptide can effectively mitigate the septic inflammation damage which is induced by the intracellular toxin LPS, thus significantly improving the survival rate of mouses which are infected by the intracellular toxin and maintaining the body immune defense function at the same time of specifically inhibiting the excessive stimulation of the LPS on the inflammatory cells. The antagonistic peptide can be used for preparing the treatment drugs of the inflammatory diseases which are caused by gram-negative bacteria and are related to a toll-like receptor protein.
Owner:INST OF FIELD OPERATION SURGERY NO 3 MILITARY MEDICL UNIV PLA
Preparation method of immune cell exosome carrying chimeric antigen receptor and application thereof
ActiveCN108315305AEnhanced tissue penetrationAbility to overcome adverse reactionsOrganic active ingredientsMammal material medical ingredientsAntigenDisease
The invention relates to the field of biological medicine, in particular to a preparation method for obtaining immune cell exosome carrying a CAR through separation. Specifically CAR immune cell is activated through specific antigen, produced exosome is further analyzed, separated, purified and enriched, and finally the immune cell exosome carrying the CAR is obtained. The exosome can be applied to the treatment of various diseases, such as cancer and severe infectious diseases, overcomes adverse reactions, such as immune inflammation storm, during CAR cell therapy, enhances the CAR tissue infiltration capacity, further has the advantages of high convenience in storage and transportation, and provides a novel strategy for the treatment of relevant diseases.
Owner:PHARCHOICE THERAPEUTICS INC
Toll-like receptor 9 (TLR9) blocking agent and application thereof
InactiveCN101712957AClearly targetedHigh blocking activityOrganic active ingredientsAntipyreticNucleotideToll-like receptor
The invention relates to a specific blocking agent of a Toll-like receptor 9 (TLR9). The blocking agent is a nonmethylated CpG nucleotide sequence segment, the core structure of which is a CGCG nucleotide sequence, and the length of the nonmethylated CpG nucleotide sequence segment is 12-30 nucleotides. The blocking agent can be specifically combined with the TLR9, can block the combination between other irritant aglucons and the TLR9 and inhibit the proinflammatory effect mediated by the receptor, and can be used for the adjuvant treatment of inflammatory resistance and allergy resistance and the preparation of an experiment reagent of immune inflammation.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
GLP-1 acceptor agonists used for treating pains
The invention relates to glucagon-like peptide-1 (GLP-1) acceptor agonists (comprising: macromolecular agonists, such as GLP-1 and derivatives thereof, and exendins and derivatives thereof; and micromolecular agonists, such as geniposides) used for treating diseases, such as pains, especially chronic pains, comprising neuropathic pains, cancer pains, diabetic pains, immune inflammation pains, pains in back and loin, and the like which can be treated through activating a central nervous system comprising a spinal cord GLP-1 acceptor.
Owner:王永祥
New medical application of paeonol and derivatives thereof
InactiveCN102166205AReduce inflammationEffective treatmentSenses disorderKetone active ingredientsUveitisConjunctiva
The invention relates to new application of paeonol and derivatives thereof in the pharmacy field. The animal experiment research shows that paeonol and derivatives thereof can obviously relieve or eliminate the inflammatory reaction of the local tissue of the eye with immunologic conjunctivitis, obviously reduce the infiltration of acidophilic cells and the degranulation of mast cells in the conjunctiva tissue, obviously relieve the inflammatory reaction of the anterior segment of the eye with uveitis, reduce the infiltration of inflammatory cells in the vitreous body and retinal tissue, effectively control the non-infectious immune inflammation of the dry eye, and obviously relieve the inflammatory reaction of the animal model eye with chronic conjunctivitis; and the clinical experiment research shows that the paeonol can be used for effectively treating eye diseases such as sclerotitis and the like. The invention provides a medicament for treating eye diseases, which has the advantages of exact curative effect and wide source and is safe and convenient; and the medicament can be combined with one or more pharmaceutically acceptable carriers or excipients to be prepared into a pharmaceutical composition or preparation of the paeonol and derivatives thereof.
Owner:张筱梅
Heterocyclyl pyrimidine analogues as TYK2 inhibitors
ActiveUS9296725B2Effective treatmentOrganic active ingredientsOrganic chemistryPyrimidine analogueDisease
Owner:CELLZOME LTD
Humanized antibodies against light and uses thereof
The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
Owner:TEVA BIOPHARM USA
Extract for treating rheumatoid arthritis
InactiveCN102078395AEasy to detectEasy to takeAntipyreticAnalgesicsTreatment effectTriterpenoid saponin
The invention relates to an extract of traditional Chinese medicine unifoliate clematis and an application of the extract as a medicine for treating rheumatoid arthritis. The extract is a unifoliate clematis extract which takes the traditional Chinese medicine unifoliate clematis as a raw material, is produced under certain technological conditions and contains various triterpenoid saponin components. The pharmacological experiments of animal general inflammation and immune inflammation models prove that the extract provided by the invention has an obvious treatment effect and has an important value for treating rheumatoid arthritis.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Heterocyclic group contained amino-methanol derivative, its salt, its synthetic method and its use
Owner:FORELAND PHARM CO LTD
Callicarpa kwangtungensis extract separation preparation method and application of callicarpa kwangtungensis extract
ActiveCN107149631ARealize comprehensive utilizationHas dispelling blood stasisDigestive systemPlant ingredientsMedicineCallicarpa kwangtungensis
The invention relates to a preparation method for acquiring effective substance groups with anti-ulcerative-colitis activity by separation from callicarpa kwangtungensis and compound extract thereof and application of the effective substance groups to preparation of medicines for treating immune inflammations. Particularly, the effective substance groups are acquired by adoption of a membrane separation focused separation technology and used for preparation of medicines for treating immune inflammations including ulcerative colitis.
Owner:CHINA PHARM UNIV
Ginsenoside Rb1 and Rd combination and application thereof to preparation of medicine for treating photoreceptor cell death related diseases
ActiveCN106074585ADegenerative disease treatment and improvementEnhanced inhibitory effectOrganic active ingredientsSenses disorderDiseaseDiabetes retinopathy
The invention relates to application of a ginsenoside Rb1 and Rd combination to preparation of a medicine for treating photoreceptor cell death related diseases. A mouse model suffering from retinal light damage is adopted to simulate the common key pathological links in the process of various degenerative retinal diseases so as to research the intervention effects of the ginsenoside Rb1 and Rd combination on the mouse model suffering from retinal light damage, and the results show that the medicinal combination can maintain the format of the retina outer nuclear layer, effectively prevent the retina outer nuclear layer from degenerative damage and thickness reduction, inhibit death of photoreceptor cells, block oxidative stress of retinal pigment epitheliums and photoreceptor cells, effectively inhibit retinal damage related immuno-inflammatory responses and remarkably improve the degenerative retinal diseases. Therefore, the ginsenoside Rb1 and Rd combination can be used for preparing the medicine for treating various degenerative retinal diseases including age-related macular degeneration, retinal pigment degeneration, Stargardt disease, cone-rod cell dystrophy, diabetic retinopathy and the like.
Owner:YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE
Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease
InactiveUS20130202712A1Prolong blood circulation timeImprove permeabilityBiocideHydroxy compound active ingredientsMedicineActive agent
The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and / or biodegradable polymeric carrier, and to the use of biocompatible and / or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent.
Owner:VINDICO NANOBIOTECHNOLOGY LLC
Iodine-loaded bioactive glass for wound care and application of iodine-loaded bioactive glass
InactiveCN110151784ABroad-spectrum antibacterialQuick fixAntibacterial agentsAntimycoticsSide effectWound care
The invention discloses iodine-loaded bioactive glass for wound care and application of the iodine-loaded bioactive glass. The properties that chitosan is not dissolved in an alkaline medium and formscondensation / precipitation when meeting an alkaline medium are utilized to obtain a chitosan microsphere template, and hollow bioactive glass is prepared from a compound containing various inorganicelements (silicon, calcium, sodium, phosphorus and the like) through a sol-gel-template method. The iodine-loaded bioactive glass is prepared by adopting a sealing temperature control sublimation andadsorption technology, and the composition has both bioactive glass particles and iodine molecules, can effectively promote healing of hard and soft tissue injuries of the human body, can also play along-lasting role of inhibiting / killing bacteria, has strong effects, low toxic and side effects and little immune inflammation response, and is convenient to store, carry and use.
Owner:ZHEJIANG UNIVERSITY OF SCIENCE AND TECHNOLOGY +1
Application of ABT-263 in preparation of medicine for inhibiting corneal transplantation immunological rejection
PendingCN113633642AProlong survival timeReduce inflammationOrganic active ingredientsPharmaceutical delivery mechanismDiseaseOphthalmology
The invention provides application of ABT-263 in preparation of a medicine for inhibiting corneal transplantation immunological rejection, and belongs to the technical field of chemical medicines. The invention provides an application of a micromolecular Bcl-2 inhibitor Navitclax(ABT-263) capable of inducing apoptosis in preparation of a product for inhibiting immunological rejection after corneal transplantation. Researches show that the Bcl-2 inhibitor ABT-263 can prolong the survival time of a corneal graft after corneal transplantation, reduce immune inflammatory response in the corneal graft, maintain transparency of the corneal graft and reduce immunological rejection, and can be used for preventing and treating diseases such as immunological rejection after corneal transplantation, corneal endothelial cell decompensation and the like.
Owner:山东第一医科大学附属青岛眼科医院
Application of tanshinone I to treatment of microglia-mediated disease
InactiveCN102552236AReduce generationReduce expressionOrganic active ingredientsNervous disorderNeuronInflammatory mediator
The invention relates to an application of tanshinone I shown in a formula I to the treatment of a microglia-mediated disease, in particular to an application of tanshinone I to the preparation of a medicament for treating and / or preventing the microglia-mediated disease, in particular to an application of tanshinone I to preparation of a medicament for treating and / or preventing psychoneuroimmunology chronic inflammatory diseases caused by microglia-mediated neurotoxic effects. The tanshinone I provided by the invention has the novel functions of remarkably suppressing microglia cell-activated and induced cell death, suppressing the generation and expression of inflammatory mediators, i.e., NO and TNF alpha of microglia cells, and remarkably lowering the cell toxicity of activated microglia cells on neurons, the tanshinone I can be applied to prevention and treatment of brain immune inflammation-related diseases such as Alzheimer's disease, Parkinson's disease, and the like. The formula I is shown in the specifications.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf
ActiveCN102875615BHigh purityHigh A contentOrganic active ingredientsSugar derivativesCannabisHydrolysate
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
Method for treating animal-derived collagen fiber material
InactiveCN102350008AUnrestricted scope of protectionEye implantsHeart valvesPolyethylene glycolCollagen fiber
The invention relates to the field of medical appliances, and particularly relates to a method for treating an animal-derived collagen fiber material. The method is performed by treating the animal-derived collagen fiber material with a salt solution containing polyethylene glycol and oxidants. After a biological valve treated by the method provided by the invention is implanted to an acceptor, immune inflammation reaction is not generated.
Owner:SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
Use of Nitrosporeusines A in drugs for treating rhinitis
The invention provides a use of Nitrosporeusines A in preparation of drugs for treating immune-inflammation and especially for treating rhinitis. A contrast test utilizing terfenadine and diclofenac sodium as control groups proves that Nitrosporeusines A has clear effects. Nitrosporeusines A is first disclosed in the invention. Nitrosporeusines A has a novel skeleton type, strong activity of treating rhinitis and substantive distinguishing features, and obviously develops rhinitis prevention and treatment.
Owner:JIANGSU KANGQIANG FOOD LIMITED
Application of ZSTK474 to preparation of medicine for treating autoimmune diseases
The invention discloses application of 2-(2-difluoromethyl benzimidazole-1-yl)-4,6-dimorpholinyl-1,3,5-triazine (ZSTK474 for short) to preparation of a medicine for treating autoimmune and inflammatory diseases. Experimental results prove that the ZSTK474 can inhibit the differentiation of human immune dendritic cells, the maturity of the lipopolysaccharide (LPS) activated human immune dendritic cells, the antigen uptake capacity of immature dendritic cells, the antigen presenting capacity of mature dendritic cells and T cell proliferation reaction stimulated by the dendritic cells, and particularly can reduce the morbidity degree of mouse experimental autoimmune encephalomyelitis, so the ZSTK474 is expected to become a medicine for treating autoimmune and inflammatory diseases such as multiple sclerosis, acute disseminated encephalomyelitis and the like clinically.
Owner:TIANJIN MEDICAL UNIV
Application of proadifen in preparation of anti-inflammation drugs
InactiveCN105434416AFacilitate resolutionEnhance anti-inflammatoryOrganic active ingredientsAntipyreticDiseaseNeutrophil granulocyte
The invention belongs to the technical field of drugs, and concretely relates to an application of proadifen and pharmaceutically acceptable salts thereof in the preparation of inflammation associated disease prevention and treatment drugs. Above inflammations comprise aseptic inflammations and immune inflammations. The use of proadifen in the preparation of anti-inflammation drugs is disclosed in the invention for the first time, and a result of copper sulfate induced zebra fish inflammation model experiment researches shows that proadifen can promote regression of neutral granulocytes in the inflammation positions, and has inflammation prevention and elimination effects. The proadifen has obvious an anti-inflammatory effect on inflammation associated diseases, and can be used to prepare the inflammation associated disease prevention and treatment drugs.
Owner:HANGZHOU LEISUO PHARMA
Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com